Published in Cancer Weekly, October 16th, 1995
The feasibility study, which is divided into three phases, calls for Baxter to fully fund, in advance, the first phase and, subject to satisfactory test results and continued interest by Baxter, the second and/or third phases. Phase three would be preceded by the execution of a mutually satisfactory license and supply agreement.
Genta and Baxter believe that inducing mature T cells...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.